31 October 2023 · Users should be aware of the constraints and assumptions in creating our annual Prescribing Outlook publications, as well as their responsibilities for use.
26 June 2019 · Advice on the use of Patient Group Directions (PGDs) to supply or administer a medication which is part of a clinical trial, study or pilot
16 November 2021 · A single Patient Group Direction (PGD) can be used to supply or administer medicines in more than one location. PGDs do not need to relate to specific premises.
3 May 2023 · We outline the responsibilities of ICBs in England as commissioners of NHS services using PGDs, and link to resources that provide further support and advice.
2 August 2024 · Ustekinumab biosimilars (Pyzchiva, Uzpruvo, Wezenla) are licensed. Learn about the indications, available formulations, supporting evidence and differences.
5 March 2024 · One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.
29 June 2022 · Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence